Tatva Chintan Pharma Chem shareholders and shareholding pattern
NSE: TATVABSE: 543321Chemicals & PetrochemicalsSmall Cap
Tatva Chintan Pharma Chem Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2021 · Issue price ₹1,083
Last close ₹1,627.80up ₹22.40 (1.40%)BSE ₹1,621.00
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,605.40.
28 Oct: open ₹1,614.00, high ₹1,660.00, low ₹1,591.00
52-week range of traded prices to 28 Oct 2026
₹1,044.10Low, 30 Mar 2026₹2,113.60High, 21 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,808 Cr999th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 60.52
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.67
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.21
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 53,15138.8% delivered
Tatva Chintan Pharma Chem's shareholding pattern for Sep 2026, filed on 16 Oct 2026, with every filing from Sep 2021: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Tatva Chintan Pharma Chem, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters72.02%
- Foreign institutions4.38%
- Indian institutions3.21%
- GovernmentsNone
- Individuals and others20.39%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Indian institutions
- Governments
- Individuals and others
| Per cent | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | |
| Indian promoters | 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 79.17% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 20.83% | 20.83% | 20.83% | 20.83% | 20.83% | 20.83% | 20.83% | 20.83% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% | 27.98% |
| Shares in issue | 2,21,65,062 | 2,21,65,062 | 2,21,65,062 | 2,21,65,062 | 2,21,65,062 | 2,21,65,062 | 2,21,65,062 | 2,21,65,062 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 | 2,33,92,055 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 1,75,48,258 | 1,75,48,258 | 1,75,48,258 | 1,75,48,258 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 0 | 0 | 0 | – | – | – | – | – | – |
| Promoters' shares locked in | 1,75,48,258 | 1,75,48,258 | 1,75,48,258 | 1,75,48,258 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 44,33,013 | 0 | 0 | 0 | – | – | – | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Tatva Chintan Pharma Chem promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Shekhar Rasiklal Somani, 23.07%. The filing names 31 more members with no shares.Promoter buying and selling
| Holder | ||
|---|---|---|
| Shekhar Rasiklal SomaniIndividuals and Hindu undivided families | 23.07% | 53,96,861 |
| Chintan Nitinkumar ShahIndividuals and Hindu undivided families | 20.94% | 48,97,219 |
| Ajay Mansukhlal PatelIndividuals and Hindu undivided families | 20.16% | 47,15,345 |
| Priti Ajay PatelIndividuals and Hindu undivided families | 3.85% | 9,00,000 |
| Chintan N Shah (HUF)Individuals and Hindu undivided families | 1.91% | 4,47,500 |
| Shital Chintan ShahIndividuals and Hindu undivided families | 0.99% | 2,31,000 |
| Kajalben Shekharkumar SomaniIndividuals and Hindu undivided families | 0.93% | 2,18,080 |
| Darshana Nitinkumar ShahIndividuals and Hindu undivided families | 0.17% | 39,628 |
| Somani Samir RasiklalIndividuals and Hindu undivided families | 0.00% | 482 |
| Archana Chandravadan ShahIndividuals and Hindu undivided families | 0.00% | 5 |
| Shitalbhai Rasiklal SomaniIndividuals and Hindu undivided families | 0.00% | 843 |
No promoter shares are reported as pledged.
Largest public holders of Tatva Chintan Pharma Chem, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goldman Sachs Funds - Goldman Sachs India Equity PortfolioForeign portfolio investors, category I | – | – | – | – | – | – | – | – | 1.89% | 2.06% | 2.30% | 2.40% | 2.54% | 2.59% | 2.59% | 2.59% | 2.59% | 2.59% | 2.59% | 2.59% | 2.59% |
| Mukul Mahavir AgrawalResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.28% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% |
| Abu Dhabi Investment Authority - MonsoonForeign portfolio investors, category I | – | – | – | – | 1.31% | 1.31% | 1.36% | 1.37% | 1.23% | – | – | – | – | – | – | – | – | – | – | – | – |
| Abu Dhabi Investment Authority - BehaveInstitutions Foreign Portfolio Investor | 1.31% | 1.31% | 1.31% | 1.31% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Plutus Wealth Management LLPOther non-institutions | 2.71% | 2.71% | 2.71% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.